Esketamine Failed Cost-Effectiveness vs. Cheaper TRD Options at $50K/QALY
Intranasal esketamine — FDA-approved for treatment-resistant depression in 2019 — failed cost-effectiveness benchmarks against four cheaper third-line options in a 2026 Hong Kong modeling st…
Read article